Clinical Trial Update: Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma [EARLY_Phase 1]

View source ↗

Summary

Completed early-phase 1 trial evaluating pyrimethamine as an NRF2 inhibitor in HPV-unrelated locally advanced head and neck squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pyrimethamine (Pyrimethamine)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Head and Neck Cancer, Cancer of the Head and Neck | EARLY_Phase 1 | Status: COMPLETED